MedTrace Logo

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product

NCT07681674 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-07-02

No results posted yet for this study

Summary

BiCAP-201 trial offers continued access to Bicycle investigational product treatments zelenectide pevedotin, nuzefatide pevedotin, and BT7480 for participants currently receiving and deriving clinical benefit from one of these treatments in a Bicycle Therapeutics-sponsored clinical trial. Bicycle Therapeutics will continue to monitor longer term safety of these treatments.

Conditions

Interventions

DRUG

Zelenectide pevedotin

Participants will continue on the same treatment regimen they were receiving in their parent study.

DRUG

BT7480

Participants will continue on the same treatment regimen they were receiving in their parent study.

DRUG

Nuzefatide pevedotin

Participants will continue on the same treatment regimen they were receiving in their parent study.

Sponsors & Collaborators

  • BicycleTx Limited

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2030-05-30
Completion
2030-05-30
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07681674 on ClinicalTrials.gov